The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy

LEON LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, GIOVANNETTI E.
Clin Cancer Res 2016 [Epub ahead of print]

continue reading →

Recent developments in the use of immunotherapy in non-small cell lung cancer

Santarpia M, GIOVANNETTI E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R.
Expert Rev Respir Med. 2016 May 5. [Epub ahead of print]

continue reading →

Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment

Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, GIOVANNETTI E.
Expert Rev Mol Diagn. 2016 [Epub ahead of print]

continue reading →

Prospective Validation of microRNA Signatures for Detecting Pancreatic Malignant Transformation in Endoscopic-Ultrasound Guided Fine-Needle Aspiration Biopsies

Frampton AE, Krell J, Mato Prado M, Gall TMH, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, GIOVANNETTI E, Castellano L, Habib NA, Vlavianos P, Stebbing J, Jiao LR.
Oncotarget 2016 Apr 12 [Epub ahead of print]

continue reading →

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: a PAMM-EORTC perspective

Ciccolini J, Serdjebi C; Peters GJ, GIOVANNETTI E.
Cancer Chem Pharmacol  2016 Mar 23. [Epub ahead of print]

continue reading →

Feasibility of cell-free circulating tumor DNA testing for lung cancer

Santarpia M, Karachaliou N, González-Cao M, Altavilla G, GIOVANNETTI E, Rosell R.
Biomark Med. 2016;10:417-30

continue reading →

The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

Passiglia F, Caparica R, GIOVANNETTI E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C.
Exp Opin Invest New Drugs 2016;25:385-92

continue reading →

On the pharmacogenetics of non-small cell lung cancer treatment

Santarpia MC, Rolfo C, Peters GJ, Leon LG, GIOVANNETTI E.
Expert Opin Drug Metab Toxicol. 2016;12:307-17

continue reading →

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Klionsky DA, GIOVANNETTI E, et al.
Autophagy 2016;12:1-222

Link: www.ncbi.nlm.nih.gov/pubmed/26799652

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Muller IB, de Langen AJ, Honeywell RH, GIOVANNETTI E, Peters GJ.
Exp Rev Anticancer Ther 2016;16:147-57

continue reading →

Prognostic and predictive role of thymidylate synthase expression in lung cancer: the debate is still open

GIOVANNETTI E, Zucali PA, Rolfo C, Assaraf YG, Peters GJ.
J Clin Oncol 2016;34:511-2.

Link: www.ncbi.nlm.nih.gov/pubmed/26712221

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma – a step towards personalized therapy

Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, GIOVANNETTI E.
Clin Epigenetics 2015; 7:129

continue reading →

Unraveling the complexity of autophagy: potential therapeutic applications in Pancreatic Ductal Adenocarcinoma

Gomez Mellado V, GIOVANNETTI E, Peters GJ.
Sem Cancer Biol 2015;35:11-9
continue reading →

C-Met as a target for personalized therapy

Garajová I, GIOVANNETTI E, Biasco G, Peters GJ.
Transl Oncogenomics 2015; Suppl.1:13-31

continue reading →

Circulating microRNAs as diagnostic biomarkers for pancreatic cancer

Le Large TYS, Meijer LL, Mato Prado M, Kazemier G, Frampton AE, GIOVANNETTI E.
Exp Rev Mol Diagn 2015;15(12):1525-9

continue reading →

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

De Mattos-Arruda L Bottai G, Nuciforo PG, Di Tommaso L, GIOVANNETTI E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.
Oncotarget 2015; 6(35):37269-80.

continue reading →

Usefulness of measuring microRNAs in bile and plasma for pancreatic ductal adenocarcinoma (PDAC) diagnosis

Le Large TYS, Frampton AE, Meijer L, Stebbing J, Kazemier G, Giovannetti E.

Am J Gastroenterol. 2015 May;110(5):768-9. doi: 10.1038/ajg.2015.77

continue reading →

microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis

Frampton AE, Krell J, Jamieson NB, Gall TMH, GIOVANNETTI E. Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J.

Eur J Cancer. 2015 Jul;51(11):1389-404. doi: 10.1016/j.ejca.2015.04.006

continue reading →

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RTT, Lee K, Ohashi K, Heideman DAM, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E.

Oncotarget 2015 Apr 29. [Epub ahead of print]

continue reading →

MicroRNAs in Cancer Management: Big Challenges for Small Molecules

Gandellini P, Giovannetti E, Nicassio F.

Biomed Res Int. 2015;2015:982156. doi: 10.1155/2015/982156. Epub 2015 Mar 24.

continue reading →